Edison issues report on BB Biotech (BION)

  London, UK, 28 October 2025   Edison issues report on BB Biotech (SIX: BION) BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0% (in CHF terms) and its share price rose 20.0%, both comfortably outperforming BION’s benchmark, the Nasdaq Biotech Index (15.7%). The most recent quarter benefited from improving macroeconomic conditions, including the Federal Reserve’s first rate cut in September. The sector outlook remains favourable, with M&A expected to be a key performance driver as big pharmaceutical companies replenish their pipelines ahead of a looming patent cliff. Several core portfolio holdings achieved significant clinical and regulatory milestones, supporting BION’s momentum, and others are anticipated before year-end, serving as potential near-term catalysts for portfolio performance. Click here to read the full report. All reports published by Edison are available to download free of charge from its website www.edisongroup.com Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: enquiries@edisongroup.com +44 (0)20 3077 5700 Connect with Edison on:   LinkedIn www.linkedin.com/company/edison-group-/ X  www.x.com/edison_inv_res YouTube www.youtube.com/edisonitv